608 related articles for article (PubMed ID: 30380364)
1. Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.
Christopher MJ; Petti AA; Rettig MP; Miller CA; Chendamarai E; Duncavage EJ; Klco JM; Helton NM; O'Laughlin M; Fronick CC; Fulton RS; Wilson RK; Wartman LD; Welch JS; Heath SE; Baty JD; Payton JE; Graubert TA; Link DC; Walter MJ; Westervelt P; Ley TJ; DiPersio JF
N Engl J Med; 2018 Dec; 379(24):2330-2341. PubMed ID: 30380364
[TBL] [Abstract][Full Text] [Related]
2. Clonal evolution including partial loss of human leukocyte antigen genes favoring extramedullary acute myeloid leukemia relapse after matched related allogeneic hematopoietic stem cell transplantation.
Stölzel F; Hackmann K; Kuithan F; Mohr B; Füssel M; Oelschlägel U; Thiede C; Röllig C; Platzbecker U; Schetelig J; Illmer T; Schaich M; Seliger B; Hartmann A; Baretton G; Zietz C; Ehninger G; Schrock E; Bornhäuser M
Transplantation; 2012 Apr; 93(7):744-9. PubMed ID: 22314337
[TBL] [Abstract][Full Text] [Related]
3. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
4. Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.
Jan M; Leventhal MJ; Morgan EA; Wengrod JC; Nag A; Drinan SD; Wollison BM; Ducar MD; Thorner AR; Leppanen S; Baronas J; Stevens J; Lane WJ; Kekre N; Ho VT; Koreth J; Cutler CS; Nikiforow S; Alyea EP; Antin JH; Soiffer RJ; Ritz J; Lindsley RC; Ebert BL
Blood Adv; 2019 Jul; 3(14):2199-2204. PubMed ID: 31324640
[TBL] [Abstract][Full Text] [Related]
5. Haploidentical
Brissot E; Labopin M; Ehninger G; Stelljes M; Brecht A; Ganser A; Tischer J; Kröger N; Afanasyev B; Finke J; Elmaagacli A; Einsele H; Mohty M; Nagler A
Haematologica; 2019 Mar; 104(3):524-532. PubMed ID: 30361416
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells.
Adachi Y; Sakai T; Terakura S; Shiina T; Suzuki S; Hamana H; Kishi H; Sasazuki T; Arase H; Hanajiri R; Goto T; Nishida T; Murata M; Kiyoi H
Int J Hematol; 2022 Mar; 115(3):371-381. PubMed ID: 35037229
[TBL] [Abstract][Full Text] [Related]
7. HLA-DPB1 mismatch alleles represent powerful leukemia rejection antigens in CD4 T-cell immunotherapy after allogeneic stem-cell transplantation.
Herr W; Eichinger Y; Beshay J; Bloetz A; Vatter S; Mirbeth C; Distler E; Hartwig UF; Thomas S
Leukemia; 2017 Feb; 31(2):434-445. PubMed ID: 27479183
[TBL] [Abstract][Full Text] [Related]
8. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation.
Toffalori C; Zito L; Gambacorta V; Riba M; Oliveira G; Bucci G; Barcella M; Spinelli O; Greco R; Crucitti L; Cieri N; Noviello M; Manfredi F; Montaldo E; Ostuni R; Naldini MM; Gentner B; Waterhouse M; Zeiser R; Finke J; Hanoun M; Beelen DW; Gojo I; Luznik L; Onozawa M; Teshima T; Devillier R; Blaise D; Halkes CJM; Griffioen M; Carrabba MG; Bernardi M; Peccatori J; Barlassina C; Stupka E; Lazarevic D; Tonon G; Rambaldi A; Cittaro D; Bonini C; Fleischhauer K; Ciceri F; Vago L
Nat Med; 2019 Apr; 25(4):603-611. PubMed ID: 30911134
[TBL] [Abstract][Full Text] [Related]
9. KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.
Boudreau JE; Giglio F; Gooley TA; Stevenson PA; Le Luduec JB; Shaffer BC; Rajalingam R; Hou L; Hurley CK; Noreen H; Reed EF; Yu N; Vierra-Green C; Haagenson M; Malkki M; Petersdorf EW; Spellman S; Hsu KC
J Clin Oncol; 2017 Jul; 35(20):2268-2278. PubMed ID: 28520526
[TBL] [Abstract][Full Text] [Related]
10. Protective effect of cytomegalovirus reactivation on relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia patients is influenced by conditioning regimen.
Manjappa S; Bhamidipati PK; Stokerl-Goldstein KE; DiPersio JF; Uy GL; Westervelt P; Liu J; Schroeder MA; Vij R; Abboud CN; Fehniger TA; Cashen AF; Pusic I; Jacoby M; Meera SJ; Romee R
Biol Blood Marrow Transplant; 2014 Jan; 20(1):46-52. PubMed ID: 24120526
[TBL] [Abstract][Full Text] [Related]
11. Convergent epigenetic evolution drives relapse in acute myeloid leukemia.
Nuno K; Azizi A; Koehnke T; Lareau C; Ediriwickrema A; Corces MR; Satpathy AT; Majeti R
Elife; 2024 Apr; 13():. PubMed ID: 38647535
[TBL] [Abstract][Full Text] [Related]
12. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis.
Doppelhammer M; Fraccaroli A; Prevalsek D; Bücklein V; Häbe S; Schulz C; Hubmann M; Hausmann A; Claus R; Rank A; Schmid C; Tischer J
Ann Hematol; 2019 Mar; 98(3):753-762. PubMed ID: 30617644
[TBL] [Abstract][Full Text] [Related]
13. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
[TBL] [Abstract][Full Text] [Related]
14. One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing.
Valcárcel D; Sierra J; Wang T; Kan F; Gupta V; Hale GA; Marks DI; McCarthy PL; Oudshoorn M; Petersdorf EW; Ringdén O; Setterholm M; Spellman SR; Waller EK; Gajewski JL; Marino SR; Senitzer D; Lee SJ
Biol Blood Marrow Transplant; 2011 May; 17(5):640-8. PubMed ID: 20674756
[TBL] [Abstract][Full Text] [Related]
15. Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center.
Ciurea SO; Labopin M; Socie G; Volin L; Passweg J; Chevallier P; Beelen D; Milpied N; Blaise D; Cornelissen JJ; Fegueux N; Polge E; Kongtim P; Rondon G; Esteve J; Mohty M; Savani BN; Champlin RE; Nagler A
Cancer; 2018 May; 124(10):2134-2141. PubMed ID: 29469961
[TBL] [Abstract][Full Text] [Related]
16. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
17. Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse.
Gambacorta V; Beretta S; Ciccimarra M; Zito L; Giannetti K; Andrisani A; Gnani D; Zanotti L; Oliveira G; Carrabba MG; Cittaro D; Merelli I; Ciceri F; Di Micco R; Vago L
Cancer Discov; 2022 Jun; 12(6):1449-1461. PubMed ID: 35255120
[TBL] [Abstract][Full Text] [Related]
18. HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1.
Venstrom JM; Pittari G; Gooley TA; Chewning JH; Spellman S; Haagenson M; Gallagher MM; Malkki M; Petersdorf E; Dupont B; Hsu KC
N Engl J Med; 2012 Aug; 367(9):805-16. PubMed ID: 22931314
[TBL] [Abstract][Full Text] [Related]
19. Effect of HLA class II gene disparity on clinical outcome in unrelated donor hematopoietic cell transplantation for chronic myeloid leukemia: the US National Marrow Donor Program Experience.
Petersdorf EW; Kollman C; Hurley CK; Dupont B; Nademanee A; Begovich AB; Weisdorf D; McGlave P
Blood; 2001 Nov; 98(10):2922-9. PubMed ID: 11698272
[TBL] [Abstract][Full Text] [Related]
20. Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells.
Rimando JC; Chendamarai E; Rettig MP; Jayasinghe R; Christopher MJ; Ritchey JK; Christ S; Kim MY; Bonvini E; DiPersio JF
Blood; 2023 Apr; 141(14):1718-1723. PubMed ID: 36563336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
